Expression and inducibility by phenobarbital of CYP2C33, CYP2C42, CYP2C49, CYP2B22, and CYP3As in porcine liver, kidney, small intestine, and nasal tissues

Xenobiotica

Volumn 40, Issue 8, 2010, Pages 525-535

  Puccinelli, Emanuela ^a   Gervasi, Pier Giovanni ^a   Marca, Margherita La ^b   Beffy, Pascale ^a   Longo, Vincenzo ^b  

^a CNR   (Italy)

^b Institute of Agricultural Biology and Biotechnology   (Italy)

Author keywords

Phenobarbital induction; Pig CYP2Cs and CYP2B; Pig tissues

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2B22; CYTOCHROME P450 2C33; CYTOCHROME P450 2C42; CYTOCHROME P450 2C49; CYTOCHROME P450 3A; CYTOCHROME P450 3A22; CYTOCHROME P450 3A29; CYTOCHROME P450 3A46; MESSENGER RNA; PHENOBARBITAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC TRANSCRIPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; KIDNEY; LIVER; LIVER MICROSOME; MALE; NONHUMAN; NOSE; NOSE MUCOSA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; SWINE; TISSUE DISTRIBUTION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM;

SUIDAE; SUS;

ANIMALS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; INTESTINE, SMALL; KIDNEY; LIVER; MALE; NASAL MUCOSA; PHENOBARBITAL; RNA, MESSENGER; SWINE; UP-REGULATION;

EID: 77954651175     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.489125     Document Type: Article

References (52)

1. Amato G, Longo V, Mazzaccaro A, Gervasi PG. (1996). Microsomal oxidation of N,N-diethylformamide and its effect on P450-dependent monooxygenases in rat liver. Chem Res Toxicol 9: 882-890.
2. Anzenbacher P, Soucek P, AnzenbacherováE, Gut I, Hrubý K, Svoboda Z, Kvetina J. (1998). Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab Dispos 26:56-59.
3. Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I. (2007). Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17:731-742.
4. Chen Y, Ferguson SS, Negishi M, Goldstein JA. (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308:495-501.
5. Chirulli V, Marvasi L, Zaghini A, Fiorio R, Longo V, Gervasi PG. (2007). Inducibility of AhR-regulated CYP genes by beta-naphthoflavone in the liver, lung, kidney and heart of the pig. Toxicology 240:25-37.
6. Choi MH, Skipper PL, Wishnok JS, Tannenbaum SR. (2005). Characterization of testosterone 11 beta-hydroxylation catalyzed by human liver microsomal cytochromes P450. Drug Metab Dispos 33:714-718.
7. Desille M, Corcos L, L'Helgoualc'h A, Frémond B, Campion JP, Guillouzo A, Clément B. (1999). Detoxifying activity in pig livers and hepatocytes intended for xenotherapy. Transplantation 68:1437-1443.
8. Donato MT, Castell JV, Gómez-Lechón MJ. (1999). Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models. J Hepatol 31:542-549.
9. Ekins S, VandenBranden M, Ring BJ, Wrighton SA. (1997). Examination of purported probes of human CYP2B6. Pharmacogenetics 7:165-179.
10. Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. (2006). Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J Pharmacol Exp Ther 317: 1200-1209.
11. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. (2005). Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol Pharmacol 68:747-757. (Pubitemid 41206028)
12. Flanagan JU, McLaughlin LA, Paine MJ, Sutcliffe MJ, Roberts GC, Wolf CR. (2003). Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity. Biochem J 370:921-926.
13. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrère N, Maurel P. (2001). Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 29:242-251.
14. Goldstein JA, de Morais SM. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
15. Guengerich FP. (1997). Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106:161-182.
16. Guengerich FP. (2005). Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. Cytochrome P450, structure, mechanism and biochemistry, 3rd ed. New York: Kluwer Academic/Plenum Publishers, p. 377-463.
17. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. (1996). Multiple forms of human P450 expressed in Saccaharomyces cerevisiae. Biochem Pharmacol 51:1041-11030
18. Inoue K, Negishi M. (2008). Nuclear receptor CAR requires early growth response 1 to activate the human cytochrome P450 2B6 gene. J Biol Chem 283:10425-10432.
19. Ko JW, Desta Z, Flockhart DA. (1998). Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775-778.
20. Kojima M, Morozumi T. (2004). Cloning of six full-length cDNAs encoding pig cytochrome P450 enzymes and gene expression of these enzymes in the liver and kidney. J Health Sci 50: 518-529.
21. Laemmli UK. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
22. Li XQ, Björkman A, Andersson TB, Ridderström M, Masimirembwa CM. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300:399-407.
23. Longo V, Mazzaccaro A, Naldi F, Gervasi PG. (1991). Drug-metabolizing enzymes in liver, olfactory, and respiratory epithelium of cattle. J Biochem Toxicol 6:123-128.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
25. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P, Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431.
26. Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Duong NT, Battioni P, Dansette PM, Mansuy D. (1999). Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry 38:14264-14270.
27. Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D. (1996). Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 35:16205-16212.
28. Marini S, Grasso E, Longo V, Puccini P, Riccardi B, Gervasi PG. (2003). 4-Biphenylaldehyde and 9-anthraldehyde: two fluorescent substrates for determining P450 enzyme activities in rat and human. Xenobiotica 33:1-11.
29. Meier UT, Kronbach T, Meyer UA. (1985). Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal Biochem 151:286-291.
30. Messina A, Nannelli A, Fiorio R, Longo V, Gervasi PG. (2009). Expression and inducibility of CYP1A1, 1A2, 1B1 by betanaphthoflavone and CYP2B22, 3A22, 3A29, 3A46 by rifampicin in the respiratory and olfactory mucosa of pig. Toxicology 260: 47-52.
31. Miners JO, Birkett DJ. (1998). Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538.
32. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. (1998). Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relation ship to other cytochrome P450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1344.
33. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. (2002). Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 16:977-986.
34. Monshouwer M, van't Klooster GAE, Nijmeijer SM, Witkamp RF, van Miert ASJPAM. (1998). Characterization of cytochrome P450 isoenzymes in primary cultures of pig hepatocytes. Toxicol In Vitro 12:715-723.
35. Myers MJ, Farrell DE, Howard KD, Kawalek JC. (2001). Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metab Dispos 29:908-915.
36. Nannelli A, Chirulli V, Longo V, Gervasi PG. (2008). Expression and induction by rifampicin of CAR- and PXR-regulated CYP2B and CYP3A in liver, kidney and airways of pig. Toxicology 252:105-112.
37. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
38. Niimi S, Kim EY, Iwata H, Watanabe MX, Yasunaga G, Fujise Y, Tanabe S. (2007). Identification and hepatic expression profiles of cytochrome P450 1-4 isozymes in common minke whales (Balaenoptera acutorostrata). Comp Biochem Physiol B, Biochem Mol Biol 147:667-681.
39. Nishimura M, Naito S, Yokoi T. (2004). Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 19:135-149.
40. Nissen PH, WinterøAK, Fredholm M. (1998). Mapping of porcine genes belonging to two different cytochrome P450 subfamilies. Anim Genet 29:7-11.
41. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
42. Skaanild MT. (2006). Porcine cytochrome P450 and metabolism. Curr Pharm Des 12:1421-1427.
43. Skaanild MT, Friis C. (2008). Analyses of CYP2C in porcine microsomes. Basic Clin Pharmacol Toxicol 103:487-492.
44. Soucek P, Zuber R, AnzenbacherováE, Anzenbacher P, Guengerich FP. (2001). Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 1:11.
45. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL. (2000). Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28: 1440-1448.
46. Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. (2002). Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos 30:845-852.
47. Totah RA, Rettie AE. (2005). Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341-352.
48. Towbin H, Staehelin T, Gordon J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76:4350-4354.
49. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I. (2004). Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 32:666-674.
50. Zaphiropoulos PG, Skantz A, Eliasson M, Ahlberg MB. (1995). Cytochrome P450 genes expressed in porcine ovaries: identification of novel forms, evidence for gene conversion, and evolutionary relationships. Biochem Biophys Res Commun 212: 433-441.
51. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. (1990). Induction of polymorphic 4-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 30:471-475.
52. Zilly W, Breimer DD, Richter E. (1975). Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 9:219-227.